Rasna Therapeutics Stock Net Income
| RASP Stock | USD 0.0005 0.00 0.00% |
As of the 28th of January, Rasna Therapeutics holds the Coefficient Of Variation of (787.40), risk adjusted performance of (0.08), and Variance of 123.49. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rasna Therapeutics, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Rasna Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Rasna Therapeutics' valuation are summarized below:Rasna Therapeutics does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Rasna |
Rasna Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rasna Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rasna Therapeutics.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Rasna Therapeutics on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Rasna Therapeutics or generate 0.0% return on investment in Rasna Therapeutics over 90 days. Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment... More
Rasna Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rasna Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rasna Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 87.5 |
Rasna Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rasna Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rasna Therapeutics' standard deviation. In reality, there are many statistical measures that can use Rasna Therapeutics historical prices to predict the future Rasna Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (1.05) | |||
| Total Risk Alpha | (2.40) | |||
| Treynor Ratio | 0.2496 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Rasna Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Rasna Therapeutics January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 0.2596 | |||
| Mean Deviation | 2.78 | |||
| Coefficient Of Variation | (787.40) | |||
| Standard Deviation | 11.11 | |||
| Variance | 123.49 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (1.05) | |||
| Total Risk Alpha | (2.40) | |||
| Treynor Ratio | 0.2496 | |||
| Maximum Drawdown | 87.5 | |||
| Skewness | (7.87) | |||
| Kurtosis | 62.0 |
Rasna Therapeutics Backtested Returns
Rasna Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.13, which implies the firm had a -0.13 % return per unit of risk over the last 3 months. Rasna Therapeutics exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Rasna Therapeutics' Risk Adjusted Performance of (0.08), coefficient of variation of (787.40), and Variance of 123.49 to confirm the risk estimate we provide. The company holds a Beta of -5.7, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Rasna Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Rasna Therapeutics is expected to outperform it. At this point, Rasna Therapeutics has a negative expected return of -1.41%. Please make sure to check Rasna Therapeutics' risk adjusted performance, variance, as well as the relationship between the Variance and kurtosis , to decide if Rasna Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
Rasna Therapeutics has no correlation between past and present. Overlapping area represents the amount of predictability between Rasna Therapeutics time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rasna Therapeutics price movement. The serial correlation of 0.0 indicates that just 0.0% of current Rasna Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Rasna Therapeutics reported net income of (686,588). This is 100.2% lower than that of the sector and 100.98% lower than that of the Net Income industry. The net income for all United States stocks is 100.12% higher than that of the company.
Rasna Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rasna Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rasna Therapeutics could also be used in its relative valuation, which is a method of valuing Rasna Therapeutics by comparing valuation metrics of similar companies.Rasna Therapeutics is currently under evaluation in net income category among its peers.
Rasna Fundamentals
| Return On Equity | -2.94 | |||
| Return On Asset | -3.7 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 771.81 M | |||
| Shares Owned By Insiders | 85.10 % | |||
| Price To Book | 0.31 X | |||
| EBITDA | 254.41 K | |||
| Net Income | (686.59 K) | |||
| Cash And Equivalents | 10.52 K | |||
| Total Debt | 91.97 K | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (312.66 K) | |||
| Number Of Employees | 13 | |||
| Beta | -57.77 | |||
| Market Capitalization | 12.04 M | |||
| Total Asset | 85.28 K | |||
| Z Score | 84.6 | |||
| Net Asset | 85.28 K |
About Rasna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rasna Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rasna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rasna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Rasna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rasna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rasna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Rasna Pink Sheet
| 0.69 | AAPL | Apple Inc Earnings Call Tomorrow | PairCorr |
Moving against Rasna Pink Sheet
| 0.78 | TSM | Taiwan Semiconductor Aggressive Push | PairCorr |
| 0.62 | GOOG | Alphabet Class C Earnings Call This Week | PairCorr |
| 0.49 | BMYMP | Bristol Myers Squibb Earnings Call Next Week | PairCorr |
| 0.33 | PPERY | Bank Mandiri Persero Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to Rasna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rasna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rasna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rasna Therapeutics to buy it.
The correlation of Rasna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rasna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rasna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rasna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.